The World Health Organization acknowledged “evidence emerging” of the airborne spread of the novel coronavirus, after a group of scientists urged the global body to update the WHO’s guidance on how the respiratory disease passes between people.

India shipped 50 million tablets of hydroxychloroquine to the United States, an Indian source with direct knowledge of the exports said, although U.S. regulators warned the anti-malarial drug may have harmful side effects in the treatment of COVID-19.

The Fitbit on your wrist not only counts your steps and minutes of sleep, it can also help tell if you are coming down with the flu – and warn health authorities to get ready to help.

The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.

GlaxoSmithKline Plc said the company’s three-in-one drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to the British drugmaker’s lung medicines division.

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.

AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.

One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.

AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler.